How Brand-Name Drug Companies Delay Generic Competition: Product Hopping, Patent Thickets, and Market Exclusivity Tactics Explained
Generic drugs are supposed to be the systems pressure valveyet a growing body of evidence suggests the valve is getting throttled.
For patients, payers, and policymakers, the cost of delay is measured in months and years. For innovators, the incentiv…
